[The "problem obesity": viewpoint of the internist].
The prevalence of obesity has reached epidemic dimension in industrialized countries and it is known that obesity is associated with increased risk of cardiovascular morbidity and mortality. Commonly, obesity is defined by the Body Mass Index (BMI). However, BMI fails to consider body fat distribution. The relationship between the risk of metabolic-cardiovascular diseases and body fat distribution indices such as the waist-to-hip ratio (WHR) and the waist circumference, rather than measures of the degree of body fatness as expressed by BMI, has long been recognized. Recently, clinical and epidemiological research has found waist circumference to be the best anthropometric indicator of both total body fat and intra-abdominal fat mass. Android or visceral obesity is associated with metabolic syndrome and increased cardiovascular morbidity and mortality through a variety of molecular mechanisms possibly linking the metabolic syndrome to hemostatic and vascular abnormalities. Obesity guidelines suggest the need for weight reduction using behavioural change to reduce caloric intake and increasing physical activity. A realistic goal for weight reduction is to reduce body weight by 5% to 10% over a period of 6 to 12 months. Combined intervention of a low calories diet, increased physical activity, and behaviour therapy provides better outcomes for long-term weight reduction and weight maintenance than programs that use only one or two of these modalities. The drugs used to promote weight loss have been anorexic drugs or appetite suppressants. All classes of anorexic drugs affect neurotransmitters in the brain. The new agent sibutramine has norepinephrine and serotonin effects. Another new agent, orlistat, has a different mechanism of action, the reduction of fat absorption. Weight loss drugs approved by the FDA for long-term use may be useful as an adjunct to diet, physical activity and behaviour therapy for patients with a BMI of > or =30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of > or =27 with concomitant obesity-related risk factors or diseases.
Guagnano
Maria Teresa
MT
Dipartimento di Medicina e Scienza dell'Invecchiamento, Università G. d'Annunzio Chieti, Pescara.
Manigrasso
Maria Rosaria
MR
Capani
Fabio
F
Davì
Giovanni
G
D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001067:Appetite Depressants / Q000494:pharmacology; D050218:Body Fat Distribution; D015992:Body Mass Index; D031204:Caloric Restriction; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000494:pharmacology; D004038:Diet, Reducing; D004041:Dietary Fats / Q000378:metabolism; D014943:Global Health; D006801:Humans; D007388:Internal Medicine; D007408:Intestinal Absorption / Q000187:drug effects; D050152:Intra-Abdominal Fat; D007783:Lactones / Q000494:pharmacology; D024821:Metabolic Syndrome / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D009043:Motor Activity; D009767:Obesity, Morbid / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D000077403:Orlistat; D040242:Risk Reduction Behavior; D049629:Waist-Hip Ratio
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; D004041:Dietary Fats; D007783:Lactones; D000077403:Orlistat; C058254:sibutramine